This finding is not surprising because sEH inhibitors and EET analogs, respectively, represent promising and powerful therapies to prevent the progression of various chronic kidney diseases to renal failure (Imig, 2015; Fan and Roman, 2017). The gene discussed is EPHX2; the disease is acute kidney injury.